Cognition Therapeutics (CGTX)
(Delayed Data from NSDQ)
$0.51 USD
-0.02 (-2.92%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $0.50 -0.01 (-0.99%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CGTX 0.51 -0.02(-2.92%)
Will CGTX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CGTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CGTX
Cognition Therapeutics (CGTX) Gets a Buy from Oppenheimer
Positive Buy Rating Reaffirmed for Cognition Therapeutics Amid Promising Alzheimer’s Drug Data
Cognition Therapeutics’ Mixed Phase II Results Justify Hold Rating Amid Uncertain Broad Efficacy
Cognition Therapeutics releases new episode of ‘Conversations’ podcast
Cognition Therapeutics releases new episode of 'Conversations' podcast